Welcome to our dedicated page for ACLARION news (Ticker: ACONW), a resource for investors and traders seeking the latest updates and insights on ACLARION stock.
Aclarion, Inc. (Nasdaq: ACON, ACONW) generates frequent news as a commercial-stage healthcare technology company focused on chronic low back pain diagnostics. The company’s updates center on its Nociscan SaaS platform, which uses Magnetic Resonance Spectroscopy (MRS), proprietary signal processing, biomarkers, and augmented intelligence algorithms to help physicians distinguish between painful and nonpainful lumbar discs.
News about Aclarion often highlights clinical and scientific milestones. These include progress in the pivotal CLARITY randomized trial, which evaluates whether incorporating Nociscan into surgical planning can improve outcomes for patients undergoing surgery for chronic low back pain, as well as publications of real-world evidence and peer-reviewed articles describing Nociscan’s clinical and economic value. Company announcements also cover participation in major spine and neuroscience meetings and recognition in digital health award programs.
Investors and clinicians following Aclarion can expect updates on market adoption, such as growth in Nociscan scan volumes, expansion of imaging centers and physician users, and developments in reimbursement, including private insurer coverage in the United Kingdom. Corporate news includes capital raises, balance sheet developments, executive appointments, and governance events reported through both press releases and SEC filings.
This news feed aggregates these items so readers can track how Aclarion advances its Nociscan platform, builds clinical evidence, and executes its commercial strategy in the diagnostic imaging and spine care space. For those monitoring ACON and ACONW, the page provides a centralized view of company announcements, clinical trial progress, and strategic updates over time.
Aclarion (Nasdaq: ACON, ACONW) closed a $10.4 million common-stock-only financing at $5.18 per share, leaving the company with $21.6 million in cash as of Jan 12, 2026 and a debt-free balance sheet. Management says the transaction materially strengthens the balance sheet, preserves capital-structure integrity and extends the company's operating runway into 2028 under current plans. The company plans to accelerate CLARITY trial enrollment (targeting ~25% of patients by end of Q2 2026), publish multiple investigator-initiated real-world studies, expand MRI manufacturer access (>30% larger available market), launch Nociscan software v2.8 in Q1, and pursue broader US payer engagement.
Aclarion (Nasdaq: ACON / ACONW) provided a 2026 corporate outlook and 2025 operational update centered on its Nociscan platform for chronic low back pain. Key metrics: 2025 annual scan volumes +69% YoY, Q4 2025 volumes +114% YoY. The company reported a debt-free balance sheet with $12.0 million cash as of Dec 31, 2025, following >$22.0 million equity raised in 2025, and expects cash to fund operations into H1 2027. Clinical progress includes the CLARITY trial (7 activated sites) with a goal to enroll ~25% of patients by end of Q2 2026 and an initial internal 3-month readout anticipated in Q3 2026. Additional 2025 milestones: 9 new imaging centers, 22 new physician users, and 4 issued patents.
Aclarion (Nasdaq: ACON) announced first patient enrollments at two additional CLARITY trial sites (Northwestern Medicine and Scripps Health), bringing the number of sites that completed regulatory setup to seven and sites that have enrolled patients to four.
The multi-site pivotal CLARITY trial will randomize up to 300 patients to evaluate Nociscan-guided surgical planning versus blinded care. The company expects an initial interim readout after the first cohort reaches a 3-month follow-up, projected in 3Q 2026, and aims to enroll ~25% of patients by end of Q2 2026. Full enrollment target is mid-2027, with possible early termination if significance is reached earlier.
Aclarion (Nasdaq: ACON) announced publication of a featured Tech Update on its Nociscan solution in the Special Pain Issue of the International Journal of Spine Surgery (IJSS) on Dec 4, 2025. The article highlights a clinical case where a 27-year-old with chronic low back pain had MRI-suspected L4/5 and L5/S1 pathology; a four-level Nociscan exam detected biomarkers at L5/S1 only, guiding the surgeon to perform a single-level artificial disc replacement at L5/S1 that eliminated the patient’s pain and restored activity. The release emphasizes Nociscan as a noninvasive, evidence-supported SaaS platform for distinguishing painful versus nonpainful lumbar discs and notes IJSS’s role in disseminating spine care innovations to an international audience.
Aclarion (NASDAQ: ACON) announced the appointment of Jason Brosniak as Commercial Director, Eastern U.S., effective Dec 2, 2025.
Brosniak brings 20+ years in commercial roles at MedTech firms including Relievant Medsystems, Kyphon, and Intrinsic Therapeutics and will lead adoption and payer engagement for Nociscan across the densely populated Eastern U.S. The hire follows recent UK commercial expansion and coincides with growing demand from real-world evidence trials and the national CLARITY randomized controlled trial.
Nociscan is described as a SaaS platform that noninvasively quantifies chemical biomarkers to help distinguish painful versus nonpainful lumbar discs.
Aclarion (Nasdaq: ACON, ACONW) appointed Dan Isherwood as UK Commercial Director to accelerate adoption of its Nociscan solution in the UK market.
The company said Nociscan is now reimbursed by three of the top four UK private insurers, covering more than 5.2 million lives, and has early integration at a leading London spine clinic. Isherwood brings imaging and spine commercial experience from J&J MedTech, EOS Imaging, and NuVasive and earlier NHS clinical experience.
Aclarion (Nasdaq: ACON) was named a Rising Star in the Clinical Diagnostic Device category at the 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH on October 22, 2025.
The award, chosen from more than 1,800 submissions, recognizes Aclarion's Nociscan SaaS platform, which uses MR spectroscopy and proprietary AI to generate objective biomarkers to help physicians distinguish painful from non-painful lumbar discs. The company said the technology aims to improve personalized treatment decisions for chronic low back pain, a condition affecting an estimated 266 million people worldwide.
Aclarion (Nasdaq: ACON) issued a Q3 2025 corporate update highlighting accelerating commercial adoption, a strong cash position, and progress in its pivotal CLARITY trial.
Key facts: Nociscan scan volumes +89% YoY in Q3 with three consecutive record quarters; debt-free balance sheet with $13.3 million cash (≈$15.11/share) as of Oct 14, 2025; CLARITY enrolling with first patients at University of Miami and full enrollment targeted by Q4 2026; early 3-month interim readouts expected Q2 2026. Company appointed Greg Gould as CFO and will present at LD Micro on Oct 20, 2025.
Aclarion (Nasdaq: ACON) participated in the International Society of Pain and Neuroscience Annual Meeting in London on Oct 13, 2025, where a session co‑moderated by Doug Beall, M.D., highlighted the role of MR Spectroscopy and Aclarion’s Nociscan in identifying biomarkers of discogenic low back pain.
Nociscan is described as a SaaS platform that converts MR spectroscopy signals into objective biomarkers to help differentiate painful vs non‑painful lumbar discs and inform personalized treatment decisions. The company emphasized multidisciplinary clinical engagement and insurer approval at a UK clinic for study access.
Aclarion (Nasdaq: ACON) was named a finalist on Oct 7, 2025 for the 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH in the Rising Star - Clinical Diagnostic Device category.
Nociscan is described as a SaaS platform that transforms MR spectroscopy signals into objective biomarkers to noninvasively distinguish painful from non-painful lumbar discs, supporting more personalized treatment plans. The company cites an estimated 266 million people worldwide living with chronic low back pain and notes it was selected from more than 1,800 submissions.
FAQ
What is the current stock price of ACLARION (ACONW)?
